Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism 1 1Abbreviations: MTs, microtubules; MAPs, microtubule-associated proteins; MAP4, microtubule-associated protein-4; PTX, paclitaxel; EPOA, epothilone A; EPOB, epothilone B; EPOA-R, epothilone A-resistant; COL, colchicine; VCR, vincristine; and VBL, vinblastine.-Reference-Cited by-同舟云学术

Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism 1 1Abbreviations: MTs, microtubules; MAPs, microtubule-associated proteins; MAP4, microtubule-associated protein-4; PTX, paclitaxel; EPOA, epothilone A; EPOB, epothilone B; EPOA-R, epothilone A-resistant; COL, colchicine; VCR, vincristine; and VBL, vinblastine.

Published:2001-12 Issue:11 Volume:62 Page:1469-1480
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Poruchynsky Marianne S.,Giannakakou Paraskevi,Ward Yvona,Chloe Bulinski J.,Telford William G.,Robey Robert W.,Fojo Tito

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference45 articles.

1. p53, the cellular gatekeeper for growth and division;Levine;Cell,1997

2. Biochemical, cellular, and pharmacological aspects of the multidrug transporter;Ambudkar;Annu Rev Pharmacol Toxicol,1999

3. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization;Giannakakou;J Biol Chem,1997

4. Double identity for proteins of the Bcl-2 family;Reed;Nature,1997

5. BCL-2 gene family and the regulation of programmed cell death;Korsmeyer;Cancer Res,1999

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Depolymerization of tubulin as the main molecular mechanism of the cytotoxic and antitumor activity of pyrrole-containing heterocyclic compounds;Advances in Molecular Oncology;2024-06-28

2. Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options;Cells;2024-05-04

3. Tubulin Complexity in Cancer and Metastasis;Advances in Experimental Medicine and Biology;2024

4. Therapeutic strategies to overcome taxane resistance in cancer;Drug Resistance Updates;2021-03

5. Expression of Syk and MAP4 proteins in ovarian cancer;Journal of Cancer Research and Clinical Oncology;2019-02-08